ONdrugDelivery Magazine

CRITERIA FOR SELECTING A WEARABLE INJECTOR TECHNOLOGY AND PARTNER

Alan Shortall provides a detailed account of the significant opportunities that wearable injection devices present pharmaceutical and biotech companies.

FORMULATION METHODS & SIZE REDUCTION FOR INHALERS

PULMONARY

Bert Dekens

FORMULATION METHODS & SIZE REDUCTION FOR INHALERS

Bert Dekens highlights the importance of achieving the correct particle sizes, both for the API and the carrier in formulations for inhalation, and describes some of the available equipment most suited to specific tasks.

PULMONARY

Thomas Gallem

PARI

THE eFLOW “CLOSED SYSTEM”

Thomas Gallem describes the design and development stages, including the incorporation of human-factors engineering and optimisation for elderly patients, of the company’s eFlow CS nebuliser, which uses a proprietary single-dose drug ampoule as an integral part of the nebuliser handset.

GENERIC PMDI PRODUCT DEVELOPMENT FOR THE US: KEY CONSIDERATIONS

PULMONARY

Badre Hammond

Next Breath

GENERIC PMDI PRODUCT DEVELOPMENT FOR THE US: KEY CONSIDERATIONS

Badre Hammond highlights key considerations and addresses strategies that are believed to reduce risk and ultimately speed up the process for getting a generic pMDI product to the US market.

SCALE-UP & QBD APPROACHES FOR SPRAY-DRIED INHALATION FORMULATIONS

PULMONARY

Dr Eunice Costa

Hovione

SCALE-UP & QBD APPROACHES FOR SPRAY-DRIED INHALATION FORMULATIONS

Eunice Costa, Filipe Neves, Gonçalo Andrade and Conrad Winters describe the strong position of inhalable products in preclinical and clinical pipelines and make the case for formulation-based approaches to enable and enhance pulmonary product development. Spray-drying technology in particular is highlighted as a highly favourable, scalable manufacturing technique for inhalable composite particles.

CONFERENCE REVIEW

RESPIRATORY DRUG DELIVERY (RDD) 2014

Respiratory Drug Delivery^® celebrated its 25th Anniversary at the El Conquistador Resort in Fajardo, Puerto Rico, from May 4 to May 8, 2014.

MICRONEEDLES

Dr Richard Toon

DERMAL DELIVERY OF BIOLOGICS

Faz Chowdhury and Richard Toon describe one of the company’s key technologies for the delivery of biologics, the Micropatch™.

INTERVIEW

Patrick Alexandre

PATRICK ALEXANDRE, CROSSJECT

Shortly after Crossject’s successful IPO on the French NYSE Euronext Paris Exchange (Paris Bourse), Patrick Alexandre spoke about Crossject, its technology and strategy for the future as a publically traded company.

TRANSDERMAL

Dr Alan Smith

NOVEL TRANSDERMAL DELIVERY SYSTEMS FOR TREATMENT OF DIABETES

Alan Smith outlines the stages of Type 2 diabetes treatment, progressing to extenatide and insulin injections, and makes the case, using clinical data, for the transdermal route as a viable alternative to injections.

EXPERT VIEW

Bruce K Redding

TRANSDERMAL DELIVERY DEVICE DESIGN

Bruce K Redding Jnr gives an overview of the different types of transdermal patch design, as well as the various methods of getting through the skin.

TRANSDERMAL DELIVERY AS A NEW SOURCE FOR BIOPHARMA INNOVATION

EXPERT VIEW

Dr Kevin Pang

TRANSDERMAL DELIVERY AS A NEW SOURCE FOR BIOPHARMA INNOVATION

Kevin Pang discusses the potential of transdermal delivery, how it has thus far failed to live up to it and how a combination of formulation and electronic advancements mean it could soon be realised.

DESIGNING AN ULTRASOUNDENABLED PATCH FOR INSULIN

TRANSDERMAL

Bruce K Redding

DESIGNING AN ULTRASOUNDENABLED PATCH FOR INSULIN

Bruce K Redding Jr tells the story of the design and development of the U-Strip™ Insulin Transdermal Delivery System.

YOUR SOLUTION FOR SUCCESSFUL INTRADERMAL DELIVERY

MICRONEEDLES

Dr Paul Vescovo

Debiotech

YOUR SOLUTION FOR SUCCESSFUL INTRADERMAL DELIVERY

Paul Vescovo and Laurent-Dominique Piveteau discuss the design of the Debioject™ microneedle device and inserter, and its applications, particularly in intradermal delivery of vaccines.

TECHNOLOGY SHOWCASE: CROSSJECT’S ZENEO<sup>®</sup>

SKIN

Dr Tim Muller

TECHNOLOGY SHOWCASE: CROSSJECT’S ZENEO^®

ZENEO^® is a unique, automatic needle-free jet injector for SC, IM and ID routes, developed by Crossject. With ZENEO®, injection is fast, easy and secured.

CURRENT AND FUTURE OPHTHALMIC FORMULATION AND PROCESS DEVELOPMENT TRENDS

OCULAR

Brian McMillan

CURRENT AND FUTURE OPHTHALMIC FORMULATION AND PROCESS DEVELOPMENT TRENDS

Brian McMillan provides some insights into his personal experiences in the development of ophthalmic products and the significant role of innovative delivery systems in improving efficacy and reducing side-effects.

ZERO-ORDER SUSTAINED DRUG DELIVERY TO THE RETINA FROM A NANOPOROUS FILM DEVICE

OCULAR

Dr Daniel A Bernards

Oculinea

ZERO-ORDER SUSTAINED DRUG DELIVERY TO THE RETINA FROM A NANOPOROUS FILM DEVICE

Daniel Bernards, Robert Bhisitkul and Tejal Desai discuss the development of a nanoporous membrane-based implant which can significantly improve drug delivery to the back of the eye.

REVIEW OF PRESENT TECHNOLOGIES & STEPS FORWARD

OCULAR

Dr Shikha P Barman

REVIEW OF PRESENT TECHNOLOGIES & STEPS FORWARD

Shikha Barman provides an overview of the current state of play in the ocular drug delivery market.

IMPROVING OUTCOMES IN OPHTHALMOLOGY VIA SUSTAINED DRUG DELIVERY

OCULAR

Dr Tomas Navratil

IMPROVING OUTCOMES IN OPHTHALMOLOGY VIA SUSTAINED DRUG DELIVERY

Tomas Navratil, Benjamin Maynor and Benjamin Yerxa describe the company’s particle engineering technology and its application in improving the delivery of prostaglandin analogues and anti-VEGF therapy.

OCULAR

Rick Coulon

COMPANY PROFILE: ENCOMPASS

Encompass Pharma, based in Norcross, GA, US, was formed in 2004 by a highly experienced team of ophthalmic development and analytical scientists.

REDUCE RISKS, MITIGATE FAILURE & DRIVE TIMELINES IN A COMPETITIVE MARKET

OCULAR

Badre Hammond

Next Breath

REDUCE RISKS, MITIGATE FAILURE & DRIVE TIMELINES IN A COMPETITIVE MARKET

Badre Hammond, Shailuja Somaraju and Julie Suman highlight key considerations and present strategies to reduce risk and ultimately accelerate the process for gaining approval of an ophthalmic product, with a focus on the US.

OCULAR

Donna Bibber

MICRO OPHTHALMIC OCULAR IMPLANTS

Donna Bibber explores one market segment in which micro manufacturing has played and will continue to play a significant role in worldwide growth in the next five years … ophthalmic devices.

BREAKTHROUGH NANOTECHNOLOGY ENHANCES DELIVERY TO THE FRONT AND BACK OF THE EYE

OCULAR

Dr Robert Langer

Kala Bio

BREAKTHROUGH NANOTECHNOLOGY ENHANCES DELIVERY TO THE FRONT AND BACK OF THE EYE

Hongming Chen and Robert Langer discuss applications of the company’s Mucus Penetrating Particle nanotechnology in ophthalmic drug delivery.

See what ondrugdelivery's readers and contributors think

Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.